Novartis is eyeing a multibillion-dollar MedCo buyout as Jersey biotech nears NDA — reports
To get from Novartis’ US headquarters to the Medicines Company, you make a left out of a square concrete building on NJ-Route 10, follow it past the sun orange veranda of Jersey’s Hot Bagels and the inexplicable green Vermont cabin that houses the Whippany Railway Museum until you turn right and immediately arrive at a rectangular glass building. It should take you about 12 minutes.
Reports are out that Novartis may be making that trip. Amid a torrent of Phase III data burnishing MedCo’s chances at a blockbuster cholesterol drug, Bloomberg News is reporting that Novartis is looking to acquire the Jersey-based biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.